1.3 Million US Adults With Diabetes Ration Insulin Due to High Cost

New research unveiled Monday estimates that around 1.3 million U.S. adults with diabetes either skipped entire insulin doses, took less than needed, or put off purchases of the medicine over the past year due to its high cost, a striking indictment of a healthcare system that allows profit-seeking pharmaceutical companies to drive up prices at will.

The authors of the new study, published in the Annals of Internal Medicine, analyzed data from the 2021 National Health Interview Survey, examining a sample representative of 1.4 million U.S. adults with type 1 diabetes and 5.8 million with type 2 diabetes.

The results indicate that 16.5% of all adult insulin users across the U.S. rationed insulin in some way in the past year, with rationing more common among those with type 1 diabetes than type 2.

“Universal access to insulin, without cost barriers, is urgently needed,” Adam Gaffney, an ICU doctor at the Cambridge Health Alliance and the lead author of the study, told NBC News. “We have allowed pharmaceutical companies to set the agenda, and that is coming at the cost to our patients.”

The high price of insulin has long been a scandal in the U.S., where the list costs of the cheap-to-produce medicine are often up to 10 times higher than in other countries.

One recent report by Human Rights Watch (HRW) described insulin access in the U.S. as “a privilege that many cannot afford,” noting that “soaring medicine prices and inadequate health insurance coverage can result in unaffordable out-of-pocket costs that undermine the right to health, drive people into financial distress and debt, and disproportionately impact people who are socially and economically marginalized, reinforcing existing forms of structural discrimination.”

The new study, co-authored by David Himmelstein and Steffie Woolhandler, echoed those findings, pointing out that people without health insurance “had the highest rate of rationing… followed by those with private insurance.” People on Medicaid and Medicare reported the lowest rate of insulin rationing.

“Several factors likely underlie our findings,” the authors note. “Insulin prices in the United States are far higher than in other nations. Moreover, pharmaceutical firms have increased insulin prices year upon year, even for products that remain unchanged.”

According to public data spotlighted by HRW, Eli Lilly has hiked the list price of the commonly used insulin product Humalog by an inflation-adjusted 680% since it started selling the drug in 1996.

Gaffney, Himmelstein, and Woolhandler note that the recently enacted Inflation Reduction Act includes a provision limiting insulin copays to $35 per month for those on Medicare, a change that “may improve insulin access for seniors, who experienced substantial rationing in our study.”

But they lament that Senate Republicans stripped out an insulin copay cap for those with private insurance.

At the national level, HRW has called on Congress to “consider legislation to provide insulin to all insulin-dependent individuals in the country free-of-cost.”

Originally published at Commondreams.org.